Comparison of treatment effect on outcome measurements for baseline groups for continuous outcome measurements (prism cover test)
| Mean (SD) | Follow up completed | Primary gaze, horizontal | Primary gaze, vertical | Downward gaze, horizontal | Downward gaze, vertical | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| No of dioptres (SD) | No of dioptres (SD) | No of dioptres (SD) | No of dioptres (SD) | |||||||
| Times (months) | Pred | Pyrid | Pred | Pyrid | Pred | Pyrid | Pred | Pyrid | Pred | Pyrid |
| Pred, prednisone; Pyrid, pyridostigmine. | ||||||||||
| *No or insufficient data available for analysis | ||||||||||
| †For the comparison of outcome measure at follow-up with that at baseline within the same treatment group | ||||||||||
| ‡For the comparison of the outcome measure at follow up of 1 month and 3–6 months between the prednisone and pyridostigmine groups after adjustment for baseline level, age, sex, and antibody level. | ||||||||||
| 0 | 55 | 34 | 12.2 (12.1) | 13.3 (10.8) | 5.5 (6.2) | 5.4 (6.4) | 9.8 (10.4) | 11.1 (9.5) | 6.3 (6.2) | 5.5 (6.9) |
| 1 | 49 | 30 | 4.1 (8.3) | 13.0 (12.5) | 0.8 (2.0) | 5.0 (6.7) | 2.1 (6.0) | 10.9 (11.6) | 1.1 (3.7) | 4.6 (5.4) |
| 3–6 | 50 | 20 | 5.3 (9.4) | 6.2 (5.9) | 3.2 (6.8) | 3.0 (5.6) | 2.8 (6.6) | 8.9 (9.5) | 1.6 (3.3) | 4.2 (6.7) |
| 12 | 41 | 5 | 5.2 (11.0) | 22 (9.3)* | 1.3 (3.9) | 25* | 3.2 (8.3) | 17.7 (15)* | 1.7 (4.6) | 12* |
| 24 | 38 | 6 | 3.7 (8.1) | * | 1.1 (2.9) | * | 2.9 (7.9) | * | 0.6 (2.6) | * |
| p Value† | 0.003 | 0.12 | 0.0008 | 0.25 | 0.008 | 0.73 | 0.006 | 0.71 | ||
| p Value‡ | 0.007 | 0.11 | 0.01 | 0.02 | ||||||